13623-12-6

Basic information

• Product Name: 2-(1,1-Dimethylethyl)thiazole
• Synonyms: 2-(1,1-Dimethylethyl)thiazole;2-tert-butylthiazole
• CAS NO: 13623-12-6
• Molecular Formula: C₇H₁₁NS
• Molecular Weight: 141.23
• Mol File: 13623-12-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 174.1±9.0 °C(Predicted)
• Appearance: /
• Density: 1.017±0.06 g/cm3(Predicted)
• PKA: pK1: 3.00(+1) (25°C,μ=0.1)
• CAS DataBase Reference: 2-(1,1-Dimethylethyl)thiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1,1-Dimethylethyl)thiazole(13623-12-6)
• EPA Substance Registry System: 2-(1,1-Dimethylethyl)thiazole(13623-12-6)

Safety Data

• Hazardous Substances Data: 13623-12-6(Hazardous Substances Data)

Usage

Type of compound

Thiazole derivative

Structure

Five-membered nitrogen and sulfur containing heterocyclic compound

Odor

Strong and distinctive

Usage in food industry

Flavoring agent

Usage in fragrance industry

Perfume formulation

Pharmacological properties

Antimicrobial, anti-inflammatory

Versatility

Useful in various industries due to its chemical structure and properties

Upstream product

• 107-20-0 2-chloroethanal 
• 630-22-8 2,2-dimethylpropanethioamide 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 195135-48-9 (S)-3-acetyl-4-benzyl-2-tert-butylthiazolidine 1,1-dioxide 

Downstream Products

• 39199-34-3 2-(1,1-dimethylethyl)-4-phenyl-1,3-thiazole 
• 19968-76-4 2-tert-butyl-5-phenyl-thiazole 

Relevant articles and documents

PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR

The present invention discloses a series of pyrazolopyrimidine derivatives and use thereof in preparing a medicament for treating a disease related to PI3K, and in particular, discloses a derivative compound of formula (I), a tautomer thereof or a pharmaceutically acceptable composition thereof.

FARNESOID X RECEPTOR AGONISTS AND USES THEREOF

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.